BCRX BIOCRYST PHARMACEUTICALS INC
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 882796 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY60.3%
TTM net income YoY-3,996.8%
TTM EPS YoY-2,460.0%
Revenue 3-yr CAGR44.7%
Net income 3-yr CAGR—
Margins
Gross margin97.9%
Operating margin-30.1%
Net margin-37.4%
FCF margin38.0%
EBITDA margin-29.9%
Returns
ROE—
ROA-69.3%
ROIC (approx.)—
Asset turnover1.85x
Leverage & solvency
Liabilities / assets167.2%
Debt / equity—
Current ratio2.71x
Interest coverage-3.77x
Cash quality & payout
Operating cash flow / net income-1.02x
Accruals ratio-140.2%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $874.84M | $450.71M | $331.41M | $270.83M | $157.17M |
| Cost of revenue | $19.07M | $12.27M | $4.48M | $6.41M | $7.23M |
| Gross profit | $855.76M | $438.44M | $326.93M | $264.42M | $149.94M |
| R&D expense | $166.13M | $174.64M | $216.57M | $253.30M | $208.81M |
| SG&A expense | $348.65M | $266.35M | $214.07M | $159.37M | $118.82M |
| Operating income | $340.99M | -$2.54M | -$103.71M | -$148.44M | -$177.72M |
| Interest expense | $78.87M | $98.52M | $108.24M | $99.09M | $59.29M |
| Pretax income | $267.39M | -$86.95M | -$226.23M | -$244.38M | -$181.81M |
| Income tax | $3.53M | $1.93M | $310,000 | $2.73M | $2.25M |
| Net income | $263.86M | -$88.88M | -$226.54M | -$247.12M | -$184.06M |
| EBITDA | $342.38M | -$1.30M | -$102.05M | -$147.00M | -$176.94M |
| EPS (basic) | 1.26 | -0.43 | -1.18 | -1.33 | -1.03 |
| EPS (diluted) | 1.21 | -0.43 | -1.18 | -1.33 | -1.03 |
| Weighted avg. shares (diluted) | 218.58M | 206.70M | 192.20M | 185.91M | 179.12M |
| Balance sheet | |||||
| Cash & equivalents | $89.74M | $106.32M | $110.64M | $306.24M | $504.39M |
| Short-term investments | $185.01M | $216.14M | $278.34M | $119.54M | $3.21M |
| Receivables | $106.82M | $79.07M | $56.95M | $50.60M | $29.41M |
| Inventory | $5.40M | $8.09M | $28.68M | $27.53M | $15.79M |
| Current assets | $404.35M | $421.97M | $495.97M | $516.50M | $566.14M |
| PP&E, net | $8.78M | $7.78M | $7.91M | $8.62M | $8.71M |
| Total assets | $514.16M | $490.42M | $516.96M | $550.00M | $588.15M |
| Current liabilities | $196.07M | $160.38M | $149.99M | $105.51M | $103.72M |
| Long-term debt | $0 | $314.87M | $303.23M | $231.62M | $298.14M |
| Total debt | $0 | $314.87M | $303.23M | $231.62M | $298.14M |
| Total liabilities | $633.31M | $966.35M | $972.49M | $844.60M | $695.14M |
| Shareholders' equity | -$119.15M | -$475.93M | -$455.53M | -$294.60M | -$106.99M |
| Net debt | -$89.74M | $208.55M | $192.59M | -$74.61M | -$206.25M |
| Shares outstanding | 213.06M | 208.54M | 205.77M | 187.91M | 184.35M |
| Cash flow statement | |||||
| Operating cash flow | $347.37M | -$52.02M | -$95.14M | -$161.85M | -$142.16M |
| Capital expenditure | $2.47M | $1.12M | $2.17M | $1.35M | $2.38M |
| Free cash flow | $344.90M | -$53.14M | -$97.31M | -$163.20M | -$144.54M |
| Investing cash flow | -$13.69M | $52.59M | -$131.50M | -$128.24M | $15.80M |
| Financing cash flow | -$349.93M | -$5.76M | $32.48M | $88.03M | $359.67M |
| Depreciation & amortization | $1.39M | $1.25M | $1.66M | $1.44M | $777,000 |
| Stock-based compensation | $85.07M | $65.41M | $55.62M | $44.70M | $34.64M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.